Several other analysts also recently weighed in on SELB. Mizuho dropped their target price on shares of Selecta Biosciences to $4.00 and set a buy rating on the stock in a research report on Monday, February 4th. Janney Montgomery Scott reaffirmed a buy rating on shares of Selecta Biosciences in a research note on Tuesday, October 23rd. BidaskClub lowered shares of Selecta Biosciences from a hold rating to a sell rating in a research note on Saturday, October 27th. Needham & Company LLC lowered their target price on shares of Selecta Biosciences to $12.00 and set a buy rating for the company in a research note on Monday, January 28th. Finally, ValuEngine lowered shares of Selecta Biosciences from a buy rating to a hold rating in a research note on Thursday, January 24th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $15.46.
SELB traded up $0.14 during trading on Tuesday, hitting $2.13. The company’s stock had a trading volume of 179,509 shares, compared to its average volume of 468,884. Selecta Biosciences has a one year low of $1.41 and a one year high of $16.55. The company has a market capitalization of $50.34 million, a PE ratio of -0.67 and a beta of 1.39.
In related news, Director Amir Nashat bought 1,166,666 shares of the company’s stock in a transaction on Friday, January 25th. The shares were purchased at an average cost of $1.50 per share, with a total value of $1,749,999.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 25.20% of the stock is owned by company insiders.
Several large investors have recently added to or reduced their stakes in SELB. BlackRock Inc. grew its holdings in shares of Selecta Biosciences by 1.5% during the 3rd quarter. BlackRock Inc. now owns 897,480 shares of the company’s stock worth $13,956,000 after purchasing an additional 12,916 shares in the last quarter. Vanguard Group Inc grew its position in Selecta Biosciences by 1.1% during the third quarter. Vanguard Group Inc now owns 655,771 shares of the company’s stock worth $10,197,000 after buying an additional 6,859 shares in the last quarter. Artal Group S.A. lifted its stake in Selecta Biosciences by 6.8% during the fourth quarter. Artal Group S.A. now owns 600,000 shares of the company’s stock worth $1,596,000 after purchasing an additional 38,460 shares during the last quarter. FMR LLC lifted its stake in Selecta Biosciences by 23.5% during the fourth quarter. FMR LLC now owns 345,046 shares of the company’s stock worth $918,000 after purchasing an additional 65,623 shares during the last quarter. Finally, Man Group plc lifted its stake in Selecta Biosciences by 139.1% during the third quarter. Man Group plc now owns 257,315 shares of the company’s stock worth $4,001,000 after purchasing an additional 149,685 shares during the last quarter. 51.45% of the stock is owned by institutional investors.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Recommended Story: What is Cost of Debt?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.